The Food and Drug Administration (FDA) has issued a warning regarding the use of unapproved versions of glucagon-like peptide-1 (GLP-1) receptor agonist drugs, which are often used for weight loss. The agency highlighted potential risks associated with these products.
The FDA also advised health care providers to be careful when determining doses, titration, and dosing schedules for patients who are taking compounded semaglutide and tirzepatide products.
The agency is urging individuals to report any adverse events or issues related to GLP-1 medications through the FDA’s MedWatch Adverse Event Reporting Program.
Alerts Sign-up